La chaîne d'options affiche les données clés des options sur actions de Compass Pathways à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Compass Pathways..

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on CMPS stock, giving a Buy rating on November 4. Sumant Kulkarni's r...

Strategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price Target

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up

H.C. Wainwright lowered the firm's price target on Atai Life Sciences (ATAI) to $10 from $15 and keeps a Buy rating on the shares. The company repo...

Atai Life Sciences price target lowered to $10 from $15 at H.C. Wainwright

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on a clinic sale, effic...

Rising High: Numinus Wellness to sell five Utah clinics for $3.53M

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on an acquisition, an e...

Rising High: Organigram acquires Motif Labs for C$90M upfront

Earnings week ahead: FDX, NKE, CCL, BB, ACN, MU, and more

Compass Pathways (CMPS) announced its common stock will be added to the Nasdaq Biotechnology Index effective prior to market open on Monday, Decemb...

Compass Pathways to be added to Nasdaq Biotechnology Index at open on 12/23

Compass Pathways to join NASDAQ Biotechnology Index

In this edition of "Rising High," The Fly conducted an exclusive interview with Hans Eriksson, Chief Medical Officer of HMNC Brain Health, a global...

Rising High: Exclusive talk with biopharma company HMNC Brain Health

AAWH

AGMH

AMTM

ARKR

ATAI

AVXL

AYRWF

BNTX

CANN

CBSTF

CMCM

CMPS

CRLBF

CRON

CTAS

CVSI

CYBN

ENVB

FCEL

GHRS

GRWG

GTBIF

IMCC

IXHL

LVRO

MEDIF

MLKN

MNMD

MRNA

NLCP

NMTC

NVAX

PAYX

PCVX

RCAT

RHHBY

RHHVF

RICK

RLMD

SEEL

SHFS

SPRB

TCNNF

TLRY

VREOF

VRNOF

News

Health Care

Press Releases

Compass Pathways to announce second quarter financial results on August 1, 2024

Earnings

Management

Compass Pathways announces second quarter 2024 financial results and business highlights

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways to participate in three investor conferences in September

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways to Participate in December Investor Conferences

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

COLL

Abeona Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

aTyr Pharma

Benitec Biopharma

C4 Therapeutics

Cidara Therapeutics

Chimerix

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Tango Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

HC Wainwright & Co.

Maxim Group

RBC Capital

Canaccord Genuity

Morgan Stanley

Comments

Compass Pathways

Compass Pathways (CMPS) Options

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL